A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease

International Journal of Clinical Practice

Volumn 65, Issue 7, 2011, Pages 790-796

  Articus, K ^a   Baier, M ^a   Tracik, F ^a,b   Kuhn F ^c   Preuss U W ^d   Kurz, A ^e  

^a Novartis Pharma GmbH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Facharzt für Psychiatrie ^*  (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONNECTIVE TISSUE DISEASE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; ERYTHEMA; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HALLUCINATION; HEART DISEASE; HUMAN; INFESTATION; INJECTION SITE INFECTION; INNER EAR DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; SKIN DISEASE; THORAX DISEASE; TRANSDERMAL PATCH; TREATMENT OUTCOME; VASCULAR DISEASE; VOMITING;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 79959315986     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02713.x     Document Type: Article

References (20)

1. Fratiglioni L, Launer LJ, Andersen K, et al., Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S10-5. (Pubitemid 30390599)
2. Cummings JL,. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
3. Bassil N, Grossberg GT,. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009; 23: 293-307.
4. Klafki HW, Staufenbiel M, Kornhuber J, et al., Therapeutic approaches to Alzheimer's disease. Brain 2006; 129: 2840-55. (Pubitemid 44684507)
5. Winblad B, Cummings J, Andreasen N, et al., A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67. (Pubitemid 46831690)
6. Winblad B, Kawata AK, Beusterien KM, et al., Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-91. (Pubitemid 46831693)
7. Small G, Bullock R,. Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement 2011; 7 (2): 177-84.
8. Small G, Dubois B,. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007; 23: 2705-13. (Pubitemid 350146408)
9. Corey-Bloom J, Anand R, Veach J,. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65. (Pubitemid 28323228)
10. Rösler M, Anand R, Cicin-Sain A, et al., Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
11. Kurz A, Farlow M, Lefèvre G,. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009; 63: 799-805.
12. Mercier F, Lefèvre G, Huang HL, et al., Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007; 23: 3199-204.
13. Lefèvre G, Pommier F, Sȩdek G, et al., Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacology 2007; 48: 246-52.
14. Cummings J, Lefèvre G, Small G, et al., Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69: S10-3. (Pubitemid 47205654)
15. Anand R, Messina J, Hartman R,. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000; 2: 68-72. (Pubitemid 30417804)
16. Singh G, Thomas SK, Arcona S, et al., Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005; 53: 1269-70. (Pubitemid 41632540)
17. Mauskopf JA, Paramore C, Lee WC, et al., Drug persistency patterns for patients treated with rivastimgine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231-39.
18. Small GW, Kaufer D, Mendiondo MS, et al., Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473-7. (Pubitemid 40467894)
19. Borah B, Sacco P, Zarotsky V,. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin 2010; 26 (8): 1957-65.
20. Feldman HH, Lane R,. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78: 1056-63.